modelPyridoxalPhosphate
Extends from Pharmacolibrary.Drugs.ATC.A.A11HA06.
Information
| name: | PyridoxalPhosphate | |
| ATC code: | A11HA06 | route: |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Pyridoxal phosphate (PLP) is the active form of vitamin B6, functioning as a coenzyme in many enzymatic reactions including amino acid, glucose, and lipid metabolism. It is primarily used as a dietary supplement in cases of vitamin B6 deficiency and for certain rare metabolic disorders. Pyridoxal phosphate is not widely used as a drug itself but is essential in human metabolism. It is not approved as a therapeutic drug for most indications but is available as a supplement.
Pharmacokinetics
No published pharmacokinetic (PK) studies reporting model parameters (such as clearance, volume of distribution, etc.) for pyridoxal phosphate in humans were found in the scientific literature as of June 2024.
References
Kasama, R, et al., & Pitone, JM (1996). Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation 27(5) 680–686. DOI:10.1016/s0272-6386(96)90103-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8629628
Gill, SK, et al., & Koren, G (2011). Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). Therapeutic drug monitoring 33(1) 115–119. DOI:10.1097/FTD.0b013e3181ff8bc5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21079545
Driskell, JA, et al., & Moak, SW (1989). Plasma pyridoxal 5'-phosphate concentrations in obese and nonobese black women residing near Petersburg, VA. The American journal of clinical nutrition 50(1) 37–40. DOI:10.1093/ajcn/50.1.37 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2750693
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)